Legal & General Group
CAMP icon

Legal & General Group’s CAMP4 Therapeutics CAMP Stock Holding History

Legal & General Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
+3,084
New +$13.3K ﹤0.01% 3259
2025
Q2 		– Sell
-708
Closed -$2.81K – 3436
2025
Q1 		$2.81K Hold
708
– – ﹤0.01% 3334
2024
Q4 		$3.7K Buy
+708
New +$5.82K ﹤0.01% 3361

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's CAMP Position: Q2 2026 in Review

Legal & General Group opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 3,084 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings. This is a return to the name: Legal & General Group previously reported a position in CAMP as recently as Q1 2025.

Legal & General Group first reported a position in CAMP in Q4 2024 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Legal & General Group held 3,084 shares of CAMP4 Therapeutics worth $13.5K as of Q2 2026.
  • CAMP4 Therapeutics was a new Legal & General Group position in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3259 holding.
  • Legal & General Group first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.